6533b85ffe1ef96bd12c1a1b

RESEARCH PRODUCT

Integrative genomic analyses identified 14-3-3 zeta as a potential molecular driver of sorafenib resistance in HCC patients

D BeckerJens U. MarquardtBeate K. StraubCarolin CzaudernaPeter P. GrimmingerJ HajdukD CastvenSophia HeinrichPeter R. GalleArndt Weinmann

subject

14-3-3-ZETAbusiness.industryCancer researchMedicinebusinessSorafenib resistancehttps://doi.org/10.1055/s-0041-1733617